News - Appointments

UK-based Silence Therapeutics Plc has appointed Mark Rothera as president and chief executive officer to lead development of its prospective siRNA therapeutics.

Mariola Söhngen has joined Proteome Sciences Plc as a director and chief executive officer, taking over from the interim CEO Ian Pike who continues as chief scientific officer.

Yilmaz Mahshid is to join the Swedish biotech company Medivir AB as chief executive officer, replacing Uli Hacksell, who will stay on the board of directors.

Ravi Rao has joined Sobi (Swedish Orphan Biovitrum AB) as its new head of research and development, replacing Milan Zdravkovic who is leaving the company.

Sven Rohmann, a medical doctor and biotech executive, has been appointed chief executive of Immunicum AB to lead clinical development of the Swedish company’s cell-based therapy for cancer.

Neil Bell, an expert in clinical development, has joined Avacta Life Sciences Ltd as chief development officer to manage human studies of the company’s lead drug, a pro-doxorubicin compound.

Erich Schlick, a venture capitalist and industrialist, has been appointed chair of the board of directors of Switzerland-based NBE-Therapeutics GmbH which is developing antibody-drug conjugates. He is currently a general partner and managing director at Wellington Partners in Munich.

Nordic Nanovector ASA has appointed Christine Wilkinson Blanc as chief medical officer to help it advance its portfolio of targeted cancer therapies.

Peter Selin, an experienced business development executive, has been appointed chief business officer at Oasmia Pharmaceutical AB, a Swedish specialty pharma company.

Thomas Burt, a venture capitalist, has become a non-executive director at Redx Pharma Plc, representing the Sofinnova Crossover Fund, a recent investor. Mr Burt has been a partner in the fund since its inception in 2017.